BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19856394)

  • 21. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
    Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
    Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E; Tosoni A; Pozzati E; Brandes AA
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53.
    Lai JC; Cheng YW; Goan YG; Chang JT; Wu TC; Chen CY; Lee H
    DNA Repair (Amst); 2008 Aug; 7(8):1352-63. PubMed ID: 18555750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP.
    Kristensen LS; Nielsen HM; Hager H; Hansen LL
    Lung Cancer; 2011 Feb; 71(2):130-6. PubMed ID: 20627446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
    Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
    Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation of the MGMT gene is frequently detected in advanced gastric carcinoma.
    Hibi K; Sakata M; Yokomizo K; Kitamura YH; Sakuraba K; Shirahata A; Goto T; Mizukami H; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
    Anticancer Res; 2009 Dec; 29(12):5053-5. PubMed ID: 20044616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of MGMT methylation status in pituitary adenoma.
    Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
    Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
    Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
    Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical research of the MGMT expression levels in glioma pations].
    Xia HC; Zhu ZQ; Liu L; Tian HL; Sun Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Aug; 25(4):265-7. PubMed ID: 22097602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.
    Trabelsi S; Mama N; Ladib M; Karmeni N; Haddaji Mastouri M; Chourabi M; Mokni M; Tlili K; Krifa H; Yacoubi MT; Saad A; H'mida Ben Brahim D
    Clin Transl Oncol; 2016 Apr; 18(4):391-7. PubMed ID: 26289551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer.
    Lee BB; Lee EJ; Jung EH; Chun HK; Chang DK; Song SY; Park J; Kim DH
    Clin Cancer Res; 2009 Oct; 15(19):6185-91. PubMed ID: 19773381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MGMT gene is aberrantly methylated from the early stages of colorectal cancers.
    Hibi K; Goto T; Mizukami H; Kitamura Y; Sakata M; Saito M; Ishibashi K; Kigawa G; Nemoto H; Sanada Y
    Hepatogastroenterology; 2009; 56(96):1642-4. PubMed ID: 20214209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
    Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF
    BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
    Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
    Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.